Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.
about
Gene therapy in Parkinson's disease: rationale and current statusLarge-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studiesGene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryOptimizing NTS-polyplex as a tool for gene transfer to cultured dopamine neurons.Molecular chaperones in Parkinson's disease--present and futureNeurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.Endothelial cell-targeted pVEGF165 polyplex plays a pivotal role in inhibiting intimal thickening after vascular injury.Gene therapy for misfolding protein diseases of the central nervous system.alpha-Synuclein: a therapeutic target for Parkinson's disease?Consideration of gene therapy for paediatric neurotransmitter diseases.Progress and prospects: Immunobiology of gene therapy for neurodegenerative disease: prospects and risks.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity.COS-1 cells as packaging host for production of lentiviruses.Sensorimotor Cortex Injection of Adeno-Associated Viral Vector Mediates Knockout of PTEN in Neurons of the Brain and Spinal Cord of Mice.Cell transplantation and gene therapy in Parkinson's disease.Controlling Brain Cells With Light: Ethical Considerations for Optogenetic Clinical TrialsGene therapy for Parkinson's disease
P2860
Q22241423-C980FA1B-E6A8-4FD9-9617-05AE90B6206CQ24630417-F6997739-13DB-448E-82D3-EB537BC1CF61Q26851517-3AC946DF-84DE-409E-81D1-293594E7D3BFQ34540115-4F79FF33-5E4A-4BA9-912A-B81DEB953AE9Q35688796-54EF312E-3B1C-46E1-AA65-198E62F30341Q35878528-DF30DA70-A515-44ED-A300-A1D62BA8C2BEQ36094154-E52E3D7D-6594-4279-951F-64AF511AF67EQ36983203-1FB64A6D-68E8-4B5C-99EB-AF7BCBBBA466Q37070916-E5B4581A-16AD-49E9-B0A6-8F3E9D47492AQ37406055-E73E6E81-BA3E-4FEE-B854-CEB6F4047006Q37690581-F2937A35-5531-4B43-85FF-C86FB25E8589Q38112216-559ED394-793A-49F5-8370-711512811271Q39463659-E69A0BFD-A925-42D5-97B9-B6C7352ACD55Q39576647-A3C62FEF-8DFA-45C9-96BE-C7F6F1D87B58Q41598343-296A146F-AD71-4A9D-85DD-0EFE0E59366EQ44297524-8CA10286-FCA8-43DA-AE51-2900E84A54A2Q58106799-4F7FAF2F-88CB-47A0-AE8B-27AE463391ABQ58913419-968BC83D-0879-432C-9D22-DA1CAB35D9CE
P2860
Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Viral vectors for in vivo gene ...... and clinical grade production.
@en
type
label
Viral vectors for in vivo gene ...... and clinical grade production.
@en
prefLabel
Viral vectors for in vivo gene ...... and clinical grade production.
@en
P2860
P1476
Viral vectors for in vivo gene ...... and clinical grade production
@en
P2093
Richard O Snyder
Ronald J Mandel
P2860
P356
10.1016/J.EXPNEUROL.2007.08.008
P407
P577
2007-08-24T00:00:00Z